Abstract

Negative symptoms in schizophrenia strongly contribute to poor functional outcomes, however its pathogenesis is still unclear. Here, we found that histamine H1 receptor (H1R) expression in basal forebrain (BF) cholinergic neurons was decreased in patients with schizophrenia having negative symptoms. Deletion of H1R gene in cholinergic neurons in mice resulted in functional deficiency of cholinergic projections from the BF to the prefrontal cortex and in the formation of sensorimotor gating deficit, social impairment and anhedonia-like behavior. These behavioral deficits can be rescued by re-expressing H1R or by chemogenetic activation of cholinergic neurons in the BF. Direct chemogenetic inhibition of BF cholinergic neurons produced such behavioral deficits and also increased the susceptibility to hyperlocomotion. Our results suggest that the H1R deficiency in BF cholinergic neurons is critical for sensorimotor gating deficit, social impairments and anhedonia-like behavior. This finding may help to understand the genetic and biochemical bases of negative symptoms in schizophrenia.

Social impairment and anhedonia are common negative symptoms in patients with schizophrenia. Here, the authors show that the histamine H1 receptor in cholinergic neurons in the basal forebrain has a critical role in sensorimotor gating, social behaviour, and anhedonia-like behaviour in mice.

Details

Title
Histamine H1 receptor deletion in cholinergic neurons induces sensorimotor gating ability deficit and social impairments in mice
Author
Cheng, Li 1 ; Xu Cenglin 1   VIAFID ORCID Logo  ; Wang, Lu 2 ; An Dadao 2 ; Jiang, Lei 2 ; Zheng Yanrong 2 ; Xu, Yixin 2 ; Wang, Yi 1   VIAFID ORCID Logo  ; Wang, Yujing 2 ; Zhang, Kuo 3 ; Wang, Xiaodong 2   VIAFID ORCID Logo  ; Zhang Xiangnan 2   VIAFID ORCID Logo  ; Bao Aimin 2 ; Zhou, Yudong 2   VIAFID ORCID Logo  ; Yang, Jingyu 3 ; Duan Shumin 2   VIAFID ORCID Logo  ; Swaab, Dick F 4 ; Hu, Weiwei 2   VIAFID ORCID Logo  ; Chen, Zhong 1   VIAFID ORCID Logo 

 Zhejiang University, Institute of Pharmacology & Toxicology, NHC and CAMS Key Laboratory of Medical Neurobiology, College of Pharmaceutical Sciences, School of Basic Medical Sciences, Hangzhou, P.R. China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang Chinese Medical University, Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, College of Pharmaceutical Sciences, Hangzhou, P.R. China (GRID:grid.268505.c) (ISNI:0000 0000 8744 8924) 
 Zhejiang University, Institute of Pharmacology & Toxicology, NHC and CAMS Key Laboratory of Medical Neurobiology, College of Pharmaceutical Sciences, School of Basic Medical Sciences, Hangzhou, P.R. China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X) 
 Shenyang Pharmaceutical University, Department of Pharmacology, Shenyang, P.R. China (GRID:grid.412561.5) (ISNI:0000 0000 8645 4345) 
 Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2490847700
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.